Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Rivaroxaban is used to treat venous thromboembolism
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Reinforcing commitment to ethical and sustainable growth
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The agreement complements other PPAs for Sandoz production sites globally
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Subscribe To Our Newsletter & Stay Updated